BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine:: a new therapeutic challenge?

被引：37

作者：

Legros, L. ^{[1
]}

Hayette, S.

Nicolini, F. E.

Raynaud, S.

Chabane, K.

Magaud, J-P

Cassuto, J-P

Michallet, M.

机构：

[1] Hop Archet 1, Dept Hematol, Nice, France

[2] Ctr Hosp Lyon Sud, Lab Cytogenet & Mol Biol, F-69310 Pierre Benite, France

[3] Ctr Hosp Lyon Sud, EA3737, F-69310 Pierre Benite, France

[4] Hop Edouard Herriot, Dept Hematol, Lyon, France

[5] Hop Louis Pasteur, Hematol Lab, Nice, France

[6] Hop Edouard Herriot, Dept Hematol, Lyon, France

来源：

LEUKEMIA | 2007年 / 21卷 / 10期

关键词：

D O I：

10.1038/sj.leu.2404772

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2204 / 2206

页数：4

共 8 条

[1] Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -: A Europe Against Cancer Program [J].

Gabert, J ;

Beillard, E ;

van der Velden, VHJ ;

Bi, W ;

Grimwade, D ;

Pallisgaard, N ;

Barbany, G ;

Cazzaniga, G ;

Cayuela, JM ;

Cavé, H ;

Pane, F ;

Aerts, JLE ;

De Micheli, D ;

Thirion, X ;

Pradel, V ;

González, M ;

Viehmann, S ;

Malec, M ;

Saglio, G ;

van Dongen, JJM .

LEUKEMIA, 2003, 17 (12) :2318-2357

[2] MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation [J].

Giles, Francis J. ;

Cortes, Jorge ;

Jones, Dan ;

Bergstrom, Donald ;

Kantarjian, Hagop ;

Freedman, Steven J. .

BLOOD, 2007, 109 (02) :500-502

[3] Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results [J].

Hughes, Timothy ;

Deininger, Michael ;

Hochhaus, Andreas ;

Branford, Susan ;

Radich, Jerald ;

Kaecla, Jaspal ;

Baccarani, Michele ;

Cortes, Jorge ;

Cross, Nicholas C. P. ;

Druker, Brian J. ;

Gabert, Jean ;

Grimwade, David ;

Hehlmann, Ruediger ;

Kamel-Reid, Suzanne ;

Lipton, Jeffrey H. ;

Longtine, Janina ;

Martinelli, Giovanni ;

Saglio, Giuseppe ;

Soverini, Simona ;

Stock, Wendy ;

Goldman, John M. .

BLOOD, 2006, 108 (01) :28-37

[4] Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients:: a retrospective analysis from the French intergroup of CML (Fi(φ)-LMC GROUP) [J].

Nicolini, F. E. ;

Corm, S. ;

Le, Q. -H. ;

Sorel, N. ;

Hayette, S. ;

Bories, D. ;

Leguay, T. ;

Roy, L. ;

Giraudier, S. ;

Tulliez, M. ;

Facon, T. ;

Mahon, F. -X. ;

Cayuela, J. -M. ;

Rousselot, P. ;

Michallet, M. ;

Preudhomme, C. ;

Guilhot, F. ;

Roche-Lestienne, C. .

LEUKEMIA, 2006, 20 (06) :1061-1066

[5]

NICOLINI FE, 2007, IN PRESS HAEMATOLOGI

[6] Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia [J].

O'Brien, S ;

Kantarjian, H ;

Koller, C ;

Feldman, E ;

Beran, M ;

Andreeff, M ;

Giralt, S ;

Cheson, B ;

Keating, M ;

Freireich, E ;

Rios, MB ;

Talpaz, M .

BLOOD, 1999, 93 (12) :4149-4153

[7] HOMOHARRINGTONINE THERAPY INDUCES RESPONSES IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN LATE CHRONIC PHASE [J].

OBRIEN, S ;

KANTARJIAN, H ;

KEATING, M ;

BERAN, M ;

KOLLER, C ;

ROBERTSON, LE ;

HESTER, J ;

RIOS, M ;

ANDREEFF, M ;

TALPAZ, M .

BLOOD, 1995, 86 (09) :3322-3326

[8] Overriding imatinib resistance with a novel ABL kinase inhibitor [J].

Shah, NP ;

Tran, C ;

Lee, FY ;

Chen, P ;

Norris, D ;

Sawyers, CL .

SCIENCE, 2004, 305 (5682) :399-401

← 1 →